O Weiland

Summary

Affiliation: Karolinska Institutet
Country: Sweden

Publications

  1. ncbi request reprint [Immunoglobulin or vaccine as post-exposure prophylaxis against hepatitis A. The vaccine is sufficient for many according to the first controlled study]
    Ola Weiland
    Karolinska Institutet, Karolinska Universitetssjukhuset Huddinge, Stockholm
    Lakartidningen 105:1371-2. 2008
  2. doi request reprint Lower-than-standard dose peg-IFN alfa-2a for chronic hepatitis C caused by genotype 2 and 3 is sufficient when given in combination with weight-based ribavirin
    O Weiland
    Division of Infectious Diseases, Department of Medicine, Karolinska University Hospital Huddinge, Stockholm, Sweden
    J Viral Hepat 15:641-5. 2008
  3. ncbi request reprint Long-term follow-up of chronic hepatitis C patients with sustained virological response to alpha-interferon
    O Reichard
    Department of Infectious Diseases at Danderyd, University Hospital, Karolinska Institutet, Stockholm, Sweden
    J Hepatol 30:783-7. 1999
  4. ncbi request reprint Evolution of fibrosis during HCV recurrence after liver transplantation--influence of IL-28B SNP and response to peg-IFN and ribavirin treatment
    M Ackefors
    Division of Infectious Diseases, Department of Medicine, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden
    J Viral Hepat 20:770-8. 2013
  5. ncbi request reprint Hepatitis C virus RNA kinetics during the initial 12 weeks treatment with pegylated interferon-alpha 2a and ribavirin according to virological response
    T Carlsson
    Division of Infectious Diseases, Karolinska University Hospital Solna and Huddinge, Karolinska Institutet, Stockholm, Sweden
    J Viral Hepat 12:473-80. 2005
  6. doi request reprint Concentration-guided ribavirin dosing with darbepoetin support and peg-IFN alfa-2a for treatment of hepatitis C recurrence after liver transplantation
    M Ackefors
    Division of Infectious Diseases Division of Transplant Surgery Division of Pathology, Karolinska Institutet at Karolinska University Hospital Huddinge, Stockholm, Sweden
    J Viral Hepat 19:635-9. 2012
  7. doi request reprint HCV RNA decline in chronic HCV genotype 2 and 3 during standard of care treatment according to IL28B polymorphism
    J Stenkvist
    Division of Infectious Diseases, Department of Medicine, Karolinska University Hospital, Karolinska Institutet, Stockholm, Sweden
    J Viral Hepat 20:193-9. 2013
  8. ncbi request reprint Humoral and CD4(+) T helper (Th) cell responses to the hepatitis C virus non-structural 3 (NS3) protein: NS3 primes Th1-like responses more effectively as a DNA-based immunogen than as a recombinant protein
    U Lazdina
    Divisions of Clinical Virology, F68, and Biomedical Laboratory Technology, Department of Medicine, Karolinska Institute, Huddinge University Hospital, S-141 86 Huddinge, Sweden
    J Gen Virol 82:1299-308. 2001
  9. ncbi request reprint Hepatitis C virus kinetics during induction and standard 3 times a week interferon-alpha therapy
    T Carlsson
    Department of Infectious Diseases, Karolinska Institutet, Stockholm, Sweden
    Scand J Infect Dis 33:838-42. 2001
  10. ncbi request reprint Histological findings, genotype distribution and percentage of patients fulfilling the treatment criteria among patients with chronic hepatitis C virus infection in a single Swedish centre
    A Hollander
    Division of Infectious Diseases, Dept of Medicine, Karolinska Institute at Huddinge University Hospital, Stockholm, Sweden
    Scand J Gastroenterol 39:164-7. 2004

Collaborators

Detail Information

Publications37

  1. ncbi request reprint [Immunoglobulin or vaccine as post-exposure prophylaxis against hepatitis A. The vaccine is sufficient for many according to the first controlled study]
    Ola Weiland
    Karolinska Institutet, Karolinska Universitetssjukhuset Huddinge, Stockholm
    Lakartidningen 105:1371-2. 2008
  2. doi request reprint Lower-than-standard dose peg-IFN alfa-2a for chronic hepatitis C caused by genotype 2 and 3 is sufficient when given in combination with weight-based ribavirin
    O Weiland
    Division of Infectious Diseases, Department of Medicine, Karolinska University Hospital Huddinge, Stockholm, Sweden
    J Viral Hepat 15:641-5. 2008
    ..This combination yielded high SVR rates (85-86%) and may be cost-saving...
  3. ncbi request reprint Long-term follow-up of chronic hepatitis C patients with sustained virological response to alpha-interferon
    O Reichard
    Department of Infectious Diseases at Danderyd, University Hospital, Karolinska Institutet, Stockholm, Sweden
    J Hepatol 30:783-7. 1999
    ..This study aimed to determine the long-term outcome of hepatitis C virus (HCV)-infected patients who respond to interferon treatment with clearance of serum HCV RNA...
  4. ncbi request reprint Evolution of fibrosis during HCV recurrence after liver transplantation--influence of IL-28B SNP and response to peg-IFN and ribavirin treatment
    M Ackefors
    Division of Infectious Diseases, Department of Medicine, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden
    J Viral Hepat 20:770-8. 2013
    ..Our findings indicate that treatment for post-transplant HCV recurrence should be offered before advanced fibrosis is seen in the recipient...
  5. ncbi request reprint Hepatitis C virus RNA kinetics during the initial 12 weeks treatment with pegylated interferon-alpha 2a and ribavirin according to virological response
    T Carlsson
    Division of Infectious Diseases, Karolinska University Hospital Solna and Huddinge, Karolinska Institutet, Stockholm, Sweden
    J Viral Hepat 12:473-80. 2005
    ....
  6. doi request reprint Concentration-guided ribavirin dosing with darbepoetin support and peg-IFN alfa-2a for treatment of hepatitis C recurrence after liver transplantation
    M Ackefors
    Division of Infectious Diseases Division of Transplant Surgery Division of Pathology, Karolinska Institutet at Karolinska University Hospital Huddinge, Stockholm, Sweden
    J Viral Hepat 19:635-9. 2012
    ....
  7. doi request reprint HCV RNA decline in chronic HCV genotype 2 and 3 during standard of care treatment according to IL28B polymorphism
    J Stenkvist
    Division of Infectious Diseases, Department of Medicine, Karolinska University Hospital, Karolinska Institutet, Stockholm, Sweden
    J Viral Hepat 20:193-9. 2013
    ..This did not translate into a higher frequency of RVR or SVR. Hence, the clinical relevance of pretreatment analysis of IL28B polymorphisms in genotype 2 and 3 infected patients can be questioned in patients with expected high SVR rate...
  8. ncbi request reprint Humoral and CD4(+) T helper (Th) cell responses to the hepatitis C virus non-structural 3 (NS3) protein: NS3 primes Th1-like responses more effectively as a DNA-based immunogen than as a recombinant protein
    U Lazdina
    Divisions of Clinical Virology, F68, and Biomedical Laboratory Technology, Department of Medicine, Karolinska Institute, Huddinge University Hospital, S-141 86 Huddinge, Sweden
    J Gen Virol 82:1299-308. 2001
    ..However, as a DNA immunogen, NS3 elicits stronger Th1-like immune responses, whereas rNS3 primes a mixed Th1/Th2-like response regardless of the route, dose or adjuvant...
  9. ncbi request reprint Hepatitis C virus kinetics during induction and standard 3 times a week interferon-alpha therapy
    T Carlsson
    Department of Infectious Diseases, Karolinska Institutet, Stockholm, Sweden
    Scand J Infect Dis 33:838-42. 2001
    ..05). We conclude that induction treatment resulted in a significantly greater decline in HCV RNA levels than standard treatment...
  10. ncbi request reprint Histological findings, genotype distribution and percentage of patients fulfilling the treatment criteria among patients with chronic hepatitis C virus infection in a single Swedish centre
    A Hollander
    Division of Infectious Diseases, Dept of Medicine, Karolinska Institute at Huddinge University Hospital, Stockholm, Sweden
    Scand J Gastroenterol 39:164-7. 2004
    ..The aim of this study was to evaluate the genotype distribution, histological stage and grade, and the percentage of patients fulfilling the histological treatment criteria...
  11. ncbi request reprint Viral kinetics and treatment response in patients with hepatitis C during induction and standard interferon therapy in combination with ribavirin
    T Carlsson
    Dept of Infectious Diseases, Karolinska Institutet, Karolinska Hospital, Stockholm, Sweden
    Scand J Gastroenterol 37:1228-34. 2002
    ..We studied the HCV RNA levels during induction and standard interferon (IFN) and ribavirin treatment...
  12. ncbi request reprint [Long-term treatment with interferon-alpha can induce sarcoidosis. The connection can be stronger than earlier believed]
    Johan Grunewald
    Institutionen für medicin, Solna, Karolinska Institutet
    Lakartidningen 103:2045-8. 2006
  13. ncbi request reprint Elevated numbers of Fc gamma RIIIA+ (CD16+) effector CD8 T cells with NK cell-like function in chronic hepatitis C virus infection
    Niklas K Björkström
    Center for Infectious Medicine, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden
    J Immunol 181:4219-28. 2008
    ..Our data suggest that CD8 T cells, during chronic HCV infection in humans, continue to differentiate beyond defined stages of terminal effector cells, acquiring CD16 and NK cell-like functional properties...
  14. doi request reprint DNA vaccine therapy for chronic hepatitis C virus (HCV) infection: immune control of a moving target
    Matti Sallberg
    Karolinska Institutet at Karolinska University Hospital Huddinge, Division of Clinical Microbiology, F68, Department of Laboratory Medicine, S 141 86 Stockholm, Sweden
    Expert Opin Biol Ther 9:805-15. 2009
    ..The vaccination is intended to induce a coordinated immune-based attack on the continuously moving HCV target. If effective, this should help in clearing the infection...
  15. doi request reprint Expansion of functionally skewed CD56-negative NK cells in chronic hepatitis C virus infection: correlation with outcome of pegylated IFN-alpha and ribavirin treatment
    Veronica D Gonzalez
    Center for Infectious Medicine, Department of Medicine, Karolinska Institutet, Karolinska University Hospital Huddinge, Stockholm, Sweden
    J Immunol 183:6612-8. 2009
    ..Furthermore, high levels of these cells reveal a disturbance in innate cellular immunity that is associated with an impaired ability to respond to antiviral treatment with IFN-alpha and ribavirin...
  16. ncbi request reprint Evidence for a relation between the viral load and genotype and hepatitis C virus-specific T cell responses
    Catharina Hultgren
    Division of Clinical Virology, F68, Karolinska Institutet, Huddinge University Hospital, S 141 86 Huddinge, Sweden
    J Hepatol 40:971-8. 2004
    ..The aim of this study is to explore the relation between the viral genotype, viral load, and the endogenous T cell response...
  17. doi request reprint Similar hepatitis C virus RNA kinetics in HIV/hepatitis C virus monoinfected genotype 2 or 3 matched controls during hepatitis C virus combination therapy
    Olle Karlström
    Division of Infectious Diseases, Department of Medicine, Karolinska University Hospital Huddinge, Stockholm, Sweden
    AIDS 22:899-901. 2008
    ..Sustained virological response was achieved in 9/13 (69%) versus 20/26 (77%) patients (intent-to-treat), respectively. The lower-than-standard peg-IFN dose offered high compliance and reasonable sustained virological response rates...
  18. ncbi request reprint Health-related quality of life before, during and after combination therapy with interferon and ribavirin in unselected Swedish patients with chronic hepatitis C
    Anna Hollander
    Division of Infectious Diseases, Department of Medicine, Karolinska Institutet at Karolinska University Hospital Huddinge, Stockholm, Sweden
    Scand J Gastroenterol 41:577-85. 2006
    ..To study the relationship between health-related quality of life (HRQOL) and mode of acquisition, treatment discontinuations, drop in haemoglobin levels and treatment outcome in patients with chronic hepatitis C (CHC)...
  19. ncbi request reprint Liver transplantation for HCV cirrhosis at Karolinska University Hospital Huddinge, Stockholm
    H Gjertsen
    Department of Transplantation Surgery, Karolinska University Hospital Huddinge, Stockholm, Sweden
    Transplant Proc 38:2675-6. 2006
    ..The number of patients with HCV cirrhosis transplanted in our center is increasing. Compared with patients transplanted for other chronic liver diseases, we experienced inferior results among patients with HCV cirrhosis...
  20. ncbi request reprint Codon optimization and mRNA amplification effectively enhances the immunogenicity of the hepatitis C virus nonstructural 3/4A gene
    L Frelin
    Division of Clinical Virology, Karolinska Institutet at Huddinge University Hospital, Stockholm, Sweden
    Gene Ther 11:522-33. 2004
    ..Codon optimization and mRNA amplification effectively enhances the overall immunogenicity of NS3/4A. Thus, either, or both, of these approaches should be utilized in an NS3/4A-based HCV genetic vaccine...
  21. ncbi request reprint Effect of control selection on sustained viral response rates in genotype 2/3 HCV mono-infected versus HIV/HCV co-infected patients
    Jenny Nilsson
    Division of Infectious Diseases, Karolinska Institute, Karolinska University Hospital Huddinge, Stockholm, Sweden
    Scand J Infect Dis 42:533-9. 2010
    ....
  22. ncbi request reprint Productivity improvements in hepatitis C treatment: impact on efficacy, cost, cost-effectiveness and quality of life
    Mathias Lidgren
    Medical Management Centre, Karolinska Institutet, Stockholm, Sweden
    Scand J Gastroenterol 42:867-77. 2007
    ..The treatment of chronic hepatitis C has advanced considerably during the past 15 years. The aim of this study was to evaluate the impact of different key developments from a health-economic perspective...
  23. ncbi request reprint High adherence with a low initial ribavirin dose in combination with pegylated-IFN alpha-2a for treatment of recurrent hepatitis C after liver transplantation
    Erika Hörnfeldt
    Department of Medicine, Division of Infectious Diseases, Karolinska University Hospital Huddinge, Karolinska Institute, Stockholm, Sweden
    Scand J Infect Dis 40:259-65. 2008
    ..Hence, all patients completed a full treatment course, which also offered a reasonable efficacy...
  24. doi request reprint Rapid viral response and treatment outcome in genotype 2 and 3 chronic hepatitis C: comparison between two HCV RNA quantitation methods
    Tony Carlsson
    Division of Infectious Diseases, Department of Medicine, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden
    J Med Virol 80:803-7. 2008
    ..A rapid viral response meaning HCV RNA levels <15 IU/ml predicted a sustained viral response in 97% of patients with genotype 2 or 3...
  25. ncbi request reprint GB virus C/hepatitis G virus
    R Halasz
    Division of Clinical Virology, Karolinska Institutet, Huddinge University Hospital, Sweden
    Scand J Infect Dis 33:572-80. 2001
    ..Taken together most data suggest that GBV-C/HGV is not a major cause of liver disease despite recent data indicating that it may infect and replicate in hepatocytes...
  26. ncbi request reprint Unexpected high prevalence of IgG-antibodies to hepatitis E virus in Swedish pig farmers and controls
    Bjorn Olsen
    Department of Infectious Diseases, Umea University, and Department of Medicine, Karolinska University Hospital Huddinge, Stockholm, Sweden
    Scand J Infect Dis 38:55-8. 2006
    ..Further studies are needed to elucidate the routes for infection of indigenous HEV and if sub-clinical infections with pig associated HEV strains occur in Sweden...
  27. doi request reprint Treatment of chronic hepatitis B infection: an update of Swedish recommendations
    Magnus Lindh
    Department of Infectious Diseases, Sahlgrenska University Hospital, Goteborg, Sweden
    Scand J Infect Dis 40:436-50. 2008
    ..mpa.se and www.rav.nu.se) including 7 separate papers based on thorough literature search. The complete reference list can be received from the Medical Products Agency upon request...
  28. ncbi request reprint Features of the CD4+ T-cell response in liver and peripheral blood of hepatitis C virus-infected patients with persistently normal and abnormal alanine aminotransferase levels
    Miguel A Rico
    Institute of Hepatology, Hospital Pardo de Aravaca, Madrid, Spain
    J Hepatol 36:408-16. 2002
    ..The liver is the primary site of hepatitis C virus (HCV) replication; intrahepatic T-cell responses may influence liver disease severity...
  29. ncbi request reprint Hepatitis C virus RNA levels during initial induction or standard interferon therapy: influence of continued treatment on sustained response
    Ligita Balciuniene
    Vilnius University, Vilnius University Hospital for Infectious Diseases, Vilnius, Lithuania
    Scand J Infect Dis 35:180-5. 2003
    ..Patients with a sustained viral response had a 3-log decline in viral levels at week 4, with few exceptions. Two patients with non-response at week 12 (1 each with genotype 1 and non-1) responded after supplementation with ribavirin...
  30. ncbi request reprint Chronic hepatitis C: updated Swedish consensus
    Rune Wejstål
    Department of Infectious Diseases, Sahlgrenska University Hospital Ostra, Goteborg, Sweden
    Scand J Infect Dis 35:445-51. 2003
    ..Concurrent ART or prominent liver fibrosis requires frequent monitoring because of the increased risk for mitochondrial toxicity and liver failure...
  31. ncbi request reprint Efficacy of 24 weeks treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viremia
    Stefan Zeuzem
    Clinic of Internal Medicine II, Department of Medicine, Saarland University Hospital, Kirrbergerstrasse, 66421 Homburg Saar, Germany
    J Hepatol 44:97-103. 2006
    ..The aim of the present study was to investigate this schedule in the era of pegylated interferon-alpha plus ribavirin...
  32. ncbi request reprint Prediction of sustained virological response in chronic hepatitis C patients treated with peginterferon alfa-2a (40KD) and ribavirin
    Graham R Foster
    The Royal London Hospital, London, UK
    Scand J Gastroenterol 42:247-55. 2007
    ..The purpose of this study was to model the probability of achieving a sustained virological response in individual patients, taking into consideration various predictive factors...
  33. ncbi request reprint Serum levels of anti-NS4a and anti-NS5a predict treatment response of patients with chronic hepatitis C
    Isabelle Desombere
    Center for Vaccinology, Ghent University and Hospital, Ghent, Belgium
    J Med Virol 79:701-13. 2007
    ..In conclusion, in patients with chronic HCV infection, the decision to continue or stop treatment can be made after 1 week of treatment with (peg)-interferon alpha and ribavirin...
  34. ncbi request reprint Short statement of the first European Consensus Conference on the treatment of chronic hepatitis B and C in HIV co-infected patients
    Alfredo Alberti
    J Hepatol 42:615-24. 2005
  35. ncbi request reprint Predictive value of ALT levels for histologic findings in chronic hepatitis C: a European collaborative study
    Pierre Pradat
    Department of Hepatology, Hotel Dieu, Lyon, France
    Hepatology 36:973-7. 2002
    ..In this subset of patients, the indication of liver biopsy and the potential benefit of therapy need to be further evaluated. These results suggest the need to revisit the algorithm for liver biopsy practice...
  36. ncbi request reprint Lamivudine and famciclovir combination therapy with or without addition of interferon-alpha-2b for HBeAg-positive chronic hepatitis B: a pilot study
    Per Sangfelt
    Department of Infectious Diseases, University Hospital, Uppsala, Sweden
    Scand J Infect Dis 34:505-11. 2002
    ..In conclusion, lamivudine and famciclovir combination treatment induced seroconversion from HBeAg to anti-HBe in 4/19 patients, 2 of whom became long-term responders. Addition of IFN-alpha did not improve the seroconversion rate...
  37. doi request reprint A low-dose intradermal hepatitis B vaccine programme in health-care workers and students is highly effective and cost saving: a retrospective follow-up survey in the clinical setting
    Per Sangfelt
    Department of Infectious Diseases, Akademiska University Hospital, Uppsala University, Uppsala, Sweden
    Scand J Gastroenterol 43:465-72. 2008
    ..To evaluate compliance, serologic response and the cost-benefit of a low-dose intradermal hepatitis B vaccination programme, followed by intramuscular boosters in non-responders...